Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study

Annals of Oncology

Volumn 28, Issue 10, 2017, Pages 2581-2587

  Chapman, Paul B ^a   Robert, C ^b   Larkin, J ^c   Haanen, J B ^d   Ribas, A ^e   Hogg, D ^f   Hamid, O ^g   Ascierto, P A ^h   Testori, A ⁱ   Lorigan, P C ^j   Dummer, R ^k   Sosman, J A ^l   Flaherty, K T ^m   Chang, I ⁿ   Coleman, S ^o   Caro, I ^p   Hauschild, A ^q   McArthur, G A ^r,s  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g Angeles Clinic and Research Institute   (United States)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k UNIVERSITY OF ZURICH   (Switzerland)

^l NORTHWESTERN UNIVERSITY   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ Biometrics ^*  (United States)

^o Biosphere Medical   (United States)

^p GENENTECH INC   (United States)

^q UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^r PETER MACCALLUM CANCER CENTRE   (Australia)

^s UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

BRAF mutation; Dacarbazine; Melanoma; Vemurafenib

Indexed keywords

B RAF KINASE; DACARBAZINE; IPILIMUMAB; VEMURAFENIB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; ENZYME INHIBITOR; INDOLE DERIVATIVE; SULFONAMIDE;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BRAF GENE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; FEVER; GENE MUTATION; HEADACHE; HUMAN; HYPERKERATOSIS; INTENTION TO TREAT ANALYSIS; KERATOACANTHOMA; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN CARCINOMA; SKIN PAPILLOMA; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; SKIN TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85030529396     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx339     Document Type: Article

References (18)

1. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516
2. Larkin J, Ascierto PA, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876
3. Hauschild A, Grob J-J, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365
4. Masuda S, Izpisua Belmonte JC. Trametinib for patients with advanced melanoma. Lancet Oncol 2012; 13: e409-e410
5. Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888
6. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372: 30-39
7. Long GV, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386: 444-451
8. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
9. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532
10. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330
11. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384
12. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
13. Ascierto PA, Kirkwood JM, Grob J-J et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012; 10: 85
14. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954
15. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147
16. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867
17. V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323-332
18. Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. J Clin Oncol 2015; 33: 1889-1904